Q-omics provides the consensus-scored MIR8066 profile across patient tissues and cancer cell-line models. MIR8066 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, MIR8066 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, MIR8066 RNA expression shows 4,502 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight READ, BRCA, and STAD as cancer lineages where MIR8066 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR8066 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR8066 survival associations across molecular data types. MIR8066 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR8066 RNA expression–survival associations across cancer types. High MIR8066 expression shows unfavorable associations in READ, MESO, THCA, UCEC, LIHC and KIRC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for MIR8066 RNA expression.
This table summarizes MIR8066 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR8066. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR8066 shows lower tumor expression in BRCA and LUSC. The BRCA box plot shows higher MIR8066 RNA expression in normal versus tumor tissue (log2 FC = −1.015, t-test p = .001).
This table shows molecular features associated with MIR8066 in patient tissues and cancer cell lines. In patient samples, MIR8066 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
